155 related articles for article (PubMed ID: 2470592)
21. Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report.
Kałuzny M; Bolanowski M; Sukiennik-Kujawa M; Ponikowski P; Handkiewicz-Junak D; Jarzab B; Jawiarczyk A; Syrycka J
Endokrynol Pol; 2009; 60(5):401-6. PubMed ID: 19885812
[TBL] [Abstract][Full Text] [Related]
22. The pentagastrin test in the diagnosis of the carcinoid syndrome.
Ahlman H; Dahlström A; Grönstad K; Jaffe BM; Nilsson O; Oberg K
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S86-8. PubMed ID: 2412067
[TBL] [Abstract][Full Text] [Related]
23. Depolarization evoked co-release of tachykinins from enteric nerves in the guinea-pig proximal colon.
Lippi A; Santicioli P; Criscuoli M; Maggi CA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):245-51. PubMed ID: 9550295
[TBL] [Abstract][Full Text] [Related]
24. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
25. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
Roy RC; Carter RF; Wright PD
Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
[TBL] [Abstract][Full Text] [Related]
27. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
28. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor.
Lawrence JP; Ishizuka J; Haber B; Townsend CM; Thompson JC
Surgery; 1990 Dec; 108(6):1131-4; discussion 1134-5. PubMed ID: 1978946
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical distribution, biochemical characterization, and biological action of tachykinins in the frog adrenal gland.
Leboulenger F; Vaglini L; Conlon JM; Homo-Delarche F; Wang Y; Kerdelhue B; Pelletier G; Vaudry H
Endocrinology; 1993 Nov; 133(5):1999-2008. PubMed ID: 7691584
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of carcinoid tumor with a long-acting somatostatin analog].
Werling K; Lengyel G; Fehér E; Jakab Z; Besznyák I; Feher J
Orv Hetil; 1993 Feb; 134(6):301-5. PubMed ID: 8430017
[TBL] [Abstract][Full Text] [Related]
31. Neuropeptide K-(1-24)-peptide: storage and release by carcinoid tumors.
Conlon JM; Deacon CF; Grimelius L; Cedermark B; Murphy RF; Thim L; Creutzfeldt W
Peptides; 1988; 9(4):859-66. PubMed ID: 3226960
[TBL] [Abstract][Full Text] [Related]
32. The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin.
Frölich JC; Bloomgarden ZT; Oates JA; McGuigan JE; Rabinowitz D
N Engl J Med; 1978 Nov; 299(19):1055-7. PubMed ID: 703771
[No Abstract] [Full Text] [Related]
33. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
34. Occurrence, release, and effects of multiple tachykinins in cat colonic tissues and nerves.
Hellström PM; Söder O; Theodorsson E
Gastroenterology; 1991 Feb; 100(2):431-40. PubMed ID: 1702076
[TBL] [Abstract][Full Text] [Related]
35. Effect of octreotide, a somatostatin analogue, on release of inflammatory mediators from isolated guinea pig bladder.
Bjorling DE; Saban MR; Saban R
J Urol; 1997 Jul; 158(1):258-64. PubMed ID: 9186371
[TBL] [Abstract][Full Text] [Related]
36. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
Claure RE; Drover DD; Haddow GR; Esquivel CO; Angst MS
Can J Anaesth; 2000 Apr; 47(4):334-7. PubMed ID: 10764178
[TBL] [Abstract][Full Text] [Related]
37. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
38. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of neurokinin A, neurokinin A(3-10) and neurokinin A(4-10) from a neutral water extract of a metastatic ileal carcinoid tumour.
Theodorsson-Norheim E; Jörnvall H; Andersson M; Norheim I; Oberg K; Jacobsson G
Eur J Biochem; 1987 Aug; 166(3):693-7. PubMed ID: 3038549
[TBL] [Abstract][Full Text] [Related]
40. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
